HYPE: Weight-loss injections produce major weight loss that stays off.
But what does the evidence actually show?
Large trials show substantial average weight loss with specific approved medicines during treatment. Maintaining the loss after stopping is a separate challenge: withdrawal studies show considerable regain, so these are not established short-course cures.
What is the hype?
The size of weight changes in modern trials is genuinely different from many supplement claims. The overstatement is to treat every injection as equivalent, promise the trial average to an individual or imply that a brief course permanently changes weight regulation.
Semaglutide has a large placebo-controlled trial
STEP 1 randomised 1,961 adults with overweight or obesity, without diabetes, to semaglutide 2.4 mg weekly or placebo alongside lifestyle support. At 68 weeks, mean weight change was −14.9% versus −2.4%. This establishes a substantial treatment effect in that population. The dose describes this trial, not every currently available formulation or an individual dosing recommendation. [1]
Tirzepatide also produced substantial loss
SURMOUNT-1 randomised 2,539 adults without diabetes to three tirzepatide regimens or placebo. At 72 weeks, the highest studied group averaged −20.9% versus −3.1% with placebo. Tirzepatide acts at GIP and GLP-1 receptors. Comparing this result with STEP 1 is not a direct head-to-head ranking because participants and trial conditions differed. [2]
What happened after semaglutide was stopped?
The STEP 1 extension followed 327 participants after medication and the trial lifestyle intervention ended. One year later, the semaglutide group had regained about two-thirds of its previous loss on average. The subset was exploratory and differs from the full original trial population. It nevertheless directly challenges the claim that a completed course routinely makes the loss permanent. [3]
Benefit must be assessed alongside tolerability
Gastrointestinal adverse effects were common in the trials, and some people stopped treatment. Current MHRA information describes prescription-only use, medical eligibility, pregnancy restrictions and important potential harms including pancreatitis. The trial benefit does not make the drugs appropriate for every person who wants to be slimmer. [1] [2] [4]
The catch: limitations and uncertainty
Average results conceal a wide range of response and treatment persistence. These trials used structured support and selected eligibility criteria; outcomes can differ with diabetes, another medicine or another regimen. Industry funding should be considered, and weight change is not identical to every long-term health outcome.
What this means for you
Discuss benefit, medical suitability, side effects, cost and a long-term plan before starting. Obtain medicines through a legitimate prescriber and pharmacy, and do not switch or alter doses yourself. Severe persistent abdominal pain needs urgent assessment. Treatment is a clinical option for defined needs, not a moral test or a guaranteed route to a particular body weight.
Major treatment effects are real; lasting maintenance often requires an ongoing plan.
Research & Sources
1. Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.
STEP 1 randomised trial; published abstract.
Read the original source ↗2. Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity.
SURMOUNT-1 trial; original research record.
Read the original source ↗3. Wilding et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Published abstract; exploratory extension.
Read the original source ↗4. MHRA (updated 2026). GLP-1 medicines for weight loss and diabetes: what you need to know.
Current UK safety information.
Read the original source ↗Evidence reviewed: October 2026
This targeted editorial review considered sources available in October 2026. It is not an exhaustive systematic review. Source access and indirect evidence are identified above. Evidence vs Hype provides education, not individual diagnosis or treatment. Original AI-generated featured artwork is conceptual and does not demonstrate a study result. No commercial product was selected or endorsed.